XXXX.png
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
29 janv. 2025 17h30 HE | Silexion Therapeutics Corp
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
29 janv. 2025 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with...
XXXX.png
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
28 janv. 2025 08h29 HE | Silexion Therapeutics Corp
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...
XXXX.png
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
15 janv. 2025 20h00 HE | Silexion Therapeutics Corp
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
XXXX.png
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
15 janv. 2025 16h01 HE | Silexion Therapeutics Corp
Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
XXXX.png
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
13 janv. 2025 07h50 HE | Silexion Therapeutics Corp
Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with...
XXXX.png
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
17 déc. 2024 06h30 HE | Silexion Therapeutics Corp
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
XXXX.png
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
10 déc. 2024 08h30 HE | Silexion Therapeutics Corp
Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
09 déc. 2024 05h00 HE | Medigene AG
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...